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Background: Interferon-gamma (IFN-gamma) and interleukin-6 (IL-6) are multifunctional cytokines that regulate
immune responses, cell proliferation, and tumour development and progression, which frequently have functionally
opposing roles. The cellular responses to both cytokines are activated via the Janus kinase/signal transducer and
activator of transcription (JAK/STAT) pathway. During the past 10 years, the crosstalk mechanism between the
IFN-gamma and IL-6 pathways has been studied widely and several biological hypotheses have been proposed, but
the kinetics and detailed crosstalk mechanism remain unclear.
Results: Using established mathematical models and new experimental observations of the crosstalk between the
IFN-gamma and IL-6 pathways, we constructed a new crosstalk model that considers three possible crosstalk levels:
(1) the competition between STAT1 and STAT3 for common receptor docking sites; (2) the mutual negative
regulation between SOCS1 and SOCS3; and (3) the negative regulatory effects of the formation of STAT1/3
heterodimers. A number of simulations were tested to explore the consequences of cross-regulation between the
two pathways. The simulation results agreed well with the experimental data, thereby demonstrating the
effectiveness and correctness of the model.
Conclusion: In this study, we developed a crosstalk model of the IFN-gamma and IL-6 pathways to theoretically
investigate their cross-regulation mechanism. The simulation experiments showed the importance of the three
crosstalk levels between the two pathways. In particular, the unbalanced competition between STAT1 and STAT3
for IFNR and gp130 led to preferential activation of IFN-gamma and IL-6, while at the same time the formation of
STAT1/3 heterodimers enhanced preferential signal transduction by sequestering a fraction of the activated STATs.
The model provided a good explanation of the experimental observations and provided insights that may inform
further research to facilitate a better understanding of the cross-regulation mechanism between the two pathways.Background
The Janus kinase/signal transducer and activator of tran-
scription (JAK/STAT) pathway can be activated by a
wide range of cytokines. The binding of cytokines to
their receptors drives receptor dimerization and phos-
phorylation, which leads to the recruitment, activation
and dimerization of STATs [1-5]. STAT homodimers are
translocated to the nucleus, where they regulate the ex-
pression of target genes [6,7]. IFN-gamma was first iden-
tified in a mitogen–activated lymphocyte supernatant
based on its distinctive antiviral activity. It is widely* Correspondence: huangyx356@nenu.edu.cn; liyx486@nenu.edu.cn
1National Engineering Laboratory for Druggable Gene and Protein Screening,
Northeast Normal University, Changchun 130024, China
Full list of author information is available at the end of the article
© 2013 Qi et al.; licensee BioMed Central Ltd.
Commons Attribution License (http://creativec
reproduction in any medium, provided the orinvolved in protection against tumour development and
cancer immunoediting [4]. IFN-gamma triggers the pro-
longed activation of the transcription factor STAT1 via
the IFN-gamma receptor (IFNR) and JAK, which
induces target gene expression by binding to the
gamma-activated sequences (GAS) in the promoters of
these genes [6]. Thus, the activation of the IFN-gamma/
JAK/STAT1 pathway can prevent the expansion of many
different normal and neoplastic cells [8]. However, IL-6
also has important roles in triggering the acute phase re-
sponse of the body to injury or inflammation [2]. The re-
ceptor involved with the recognition of IL-6 can be
subdivided into the non-signalling part, i.e., glycoprotein
80 (gp80), and the signalling part, i.e., glycoprotein 130
(gp130). IL-6 attaches to gp80 and drives IL6-gp80This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the IL6-gp80-gp130-JAK complex. gp130 associates with
JAK and it is tyrosine-phosphorylated in response to IL-6
stimulation, which leads to the activation of the JAK/
STAT3 pathway and MAPK (mitogen-activated protein
kinase) cascades [2,9]. IL-6 activates target genes involved
with differentiation, survival, apoptosis and proliferation,
and it plays important roles in pro- and anti-inflammatory
functions, acute phase and immune responses in the or-
ganism, and tumour progression [2,6]. Three types of
negative regulators are involved in the regulation of the
IFN-gamma and IL-6 pathways: the suppressor of cyto-
kine signalling (SOCS), SH2 domain-containing tyrosine
phosphates 2 (SHP-2) and various cytoplasmic and nu-
clear protein tyrosine phosphates (PPs) [10,11]. SOCS1
and SOCS3 are induced by JAK/STAT pathway and they
bind to the activated receptors of IFN-gamma and IL-6,
respectively, which negatively regulate the signal transduc-
tion of IFN-gamma and IL-6 [12,13]. SHP-2 acts as a
phosphatase in activated receptor complexes of IFN-
gamma and IL-6 and it negatively regulates the activation
of STATs [14,15]. PP1 dephosphorylates STAT*s (* repre-
sents species-activation states in this study) in the cyto-
plasm, while PP2 dephosphorylates STAT*s in the
nucleus, which results in STATs being returned to the
cytosol, thereby influence the activation of STATs [16,17].
Previous studies have indicated that IFN-gamma and IL-
6 have opposing roles in cell proliferation, apoptotic death
and inflammation, which are closely related to the specific
patterns and duration of STAT activation after their stimu-
lation [6]. IFN-gamma mainly phosphorylates STAT1,
which has many pro-inflammatory effects [8,18,19]. By
contrast, IL-6 is a potent activator of STAT3, which contri-
butes to its anti-inflammatory functions [2,20,21]. How-
ever, the detailed molecular mechanism leading to the
unbalanced activation of STATs after IFN-gamma and IL-6
stimulation remains unclear. Qing et al. suggested that
tyrosine 419 in the IFN-gamma receptor subunit 1
(IFNGR1) is required for the activation of both STAT1 and
STAT3 [19]. In response to IL-6, STAT3 binds to phos-
phorylated (p)YXXQ motifs (Y767,Y814,Y905 and Y915) of
gp130, whereas STAT1 is recruited to a more restricted
consensus sequence pYXPQ (Y905 and Y915) in gp130
[2]. In addition, researchers have provided some interesting
experimental results using STAT-deficient cells. Qing et al.
showed that the activation of STAT3 in response to IFN-
gamma was much stronger and more prolonged in
STAT1-null cells than wild-type cells [19]. Costa-Pereira
et al. showed that IL-6 mediated an IFN-gamma-like re-
sponse in mouse embryo fibroblasts lacking STAT3, in-
cluding the prolonged activation of STAT1 and it
promoted the induction of multiple IFN-gamma-inducible
genes [20]. However, Regis et al. reported that the activa-
tion of STAT1 in human neoplastic T lymphocytes afterIFN-gamma stimulation was generally unaffected by
STAT3 silencing [22]. Ho et al. argued that STAT3 did not
affect the activation of STAT1 [23]. Bluyssen et al. reported
that pre-treatment of EC with IFN-gamma significantly
reduced the activation of STAT3 after induction by IL-6,
but without affecting the total amounts of STAT3 [18].
However, Kaur et al. reported that the activation of STAT1
by IFN-gamma was mainly unaffected after pre-treatment
with IL-6 or other gp130-related cytokines in SH-SY5Y
human neuroblastoma cells [24]. These experimental
results indicate that STAT1 and STAT3 may have common
binding sites within IFN-gamma and IL-6 receptors, while
the activation of STAT3 may depend on the concentration
of STAT1 and vice versa. Moreover, the interactions be-
tween IFN-gamma and IL-6 signals are not symmetric.
Thyrell et al. also reported that IFN-alpha could influ-
ence the signal response of IL-6 in multiple myeloma,
which resulted in a decrease in STAT3 homodimer DNA-
binding activity and a shift from STAT3 homodimers to
STAT1/3 heterodimers [25]. Herrero et al. observed that
pre-treatment with IFN-gamma could affect the signal re-
sponse of IL-10 in macrophages, which caused the IL-10
mediated STAT activation pattern to switch from STAT3
homodimers to STAT1/3 heterodimers [26]. Therefore,
changes between STAT homodimers and STAT1/3 het-
erodimers may represent a biologically relevant approach
to determining the crosstalk between IFN-gamma and IL-
6 pathways. However, how the formation of STAT1/3 het-
erodimers regulates the interactions between IFN-gamma
and IL-6 signals is not fully understood.
Systems biology modelling generally aims to find fairly
plausible mechanistic models that include all of the relevant
key processes in a biochemical system. It is considered to be
a powerful analytical approach to understanding the essen-
tial mechanisms of the physiological functions of normal tis-
sues and pathological progression during complex diseases
[27]. The first systems biology model of the IFN-gamma/
JAK/STAT1 pathway was developed by Yamada et al. [28].
They modelled activation of the JAK/STAT1 pathway in re-
sponse to IFN-gamma and analysed the effects of the feed-
back loop regulated by SOCS1. Later, Zi et al. conducted a
multi-parametric sensitivity analysis of the model produced
by Yamada et al. and indicated that the concentrations of
SOCS1, nuclear phosphatase PP2 and cytoplasmic STAT1,
as well as some of the reaction steps that affected those con-
centrations, were the most sensitive to perturbation [29].
The first model of the IL-6/JAK/STAT3 pathway was pro-
duced by Singh et al. [30]. Recently, Moya et al. proposed an
updated model of IL-6 and IL-10 signalling via JAK/STAT
and ERK-C/EBPβ activation [31]. The model was used to in-
vestigate dynamical features of the system such as the activ-
ity ratio of JAK/STAT and ERK-C/EBPβ with different
stimulation levels of IL-6 and IL-10. The dynamic beha-
viours of some individual molecules, such as STATs and
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gated in previous studies [28,30,31], but signalling of the
crosstalk during signal transduction by IFN-gamma and IL-
6 has still not been modelled.
In this study, we developed a crosstalk model of the
IFN-gamma and IL-6 pathways by combining previously
established mathematical models and by comprehen-
sively analyzing the interactions between the two path-
ways. The model considered three possible levels of
crosstalk between the two pathways: (1) the competition
between STAT1 and STAT3 for IFNR and gp130; (2) the
mutual negative regulation between IFN-gamma and IL-
6 via the regulators SOCS1 and SOCS3; and (3) the
restrictive effects of the formation of STAT1/3 heterodi-
mers on the activation of the transcription factors
STAT1 and STAT3. We considered a number of proto-
cols where cells were stimulated by IFN-gamma and/or
IL-6. The simulation results showed that the model pro-
vided a good explanation of the experimental observa-
tions and it provided new insights that could inform
further research to facilitate a better understanding of




Based on the model of the IFN-gamma/JAK/STAT1
pathway produced by Yamada et al. [28] and the model
of the IL-6/10/JAK/STAT3 pathway produced by Moya
et al. [31], we established a crosstalk model of the IFN-
gamma and IL-6 pathways. A schematic diagram of the
model is shown in Additional file 1: Figure S1. In this
model, the components of the two previous mathemat-
ical models, their structures and most of the parameters
were left unchanged. For simplicity, we specified that
SHP-2 could repress the activated receptors of IFN-
gamma and IL-6, while PP1 and PP2 (PPX and PPN in
Yamada et al.’s work) could dephosphorylate STAT1 and
STAT3 in the cytoplasm and the nucleus, respectively.
We removed any reactions and components that were
not connected with IFN-gamma and IL-6 signalling,
such as IL-10. Sixteen new reactions were added based
on the possible mechanisms of cross-regulation between
IFN-gamma and IL-6.
The structure of the STAT1 and STAT3 proteins contains
an oligomerization domain, a coiled-coil domain, a DNA-
binding domain, a linker domain, an SH2 domain and a
transactivation domain [32,33]. The recruitment of STAT1
and STAT3 to the activated receptor complexes is known
to be mediated by their SH2 domains and phosphorylation
of the receptor tyrosine motifs is required [34-36]. After re-
ceptor binding, the STATs are phosphorylated on a single
tyrosine residue (Tyr 701 in STAT1 and Tyr705 in STAT3)
[37,38]. Many experimental observations have shown thatSTAT1 and STAT3 may combine with the same docking
sites in IFNR and gp130 [2,19]. Thus, we hypothesized that
STAT1 and STAT3 might compete for the same phos-
phorylated docking sites in IFNR and gp130, via their SH2
domains in our model. After STAT1 and STAT3 combine
with the activated receptors complexes via IFN-gamma
and/or IL-6, they are phosphorylated and disassociate from
the receptors. Based on these considerations, the new bio-
chemical reactions (N1) - (N3) and (N4) - (N6) (see “New
biochemical reactions added to the crosstalk model” in
Additional file 1) were added to our model to simulate the
activation of STAT3 after IFN-gamma stimulation and the
activation of STAT1 after IL-6 stimulation, respectively.
The kinetic parameters of these new reactions are im-
portant because they reflect the properties of the bio-
logical system. Wiederkehr-Adam et al. indicated that
the SH2 domain of STAT1 had a much higher affinity
for the phosphotyrosine 419 motif in IFNGR1 than that
in STAT3 [39]. After IL-6 stimulation, STAT3 binds to
the flexible pYXXQ motifs in gp130, whereas STAT1 is
recruited to the more restricted consensus sequence of
pYXPQ in gp130 [2]. Based on these observations, we
hypothesized the unbalanced competitive binding of
STAT1 and STAT3 with IFNR and gp130 after IFN-
gamma and IL-6 stimulation, respectively. Additional file 1:
Tables S1-S3 show that the main effector of IL-6 sig-
nalling, STAT3, had a higher affinity for gp130 than
STAT1. Similarly, the main effector of IFN-gamma sig-
nalling, STAT1, had a higher affinity for IFNR than
STAT3.
SHP-2 and SOCS combine to regulate signal transduc-
tion by IFN-gamma and IL-6 [1,12,40]. SOCS1 inhibits
the JAK/STAT pathway by binding to the activation loop
of JAK via its SH2 domain [12]. SOCS3 can also bind to
JAK [41]. SOCS1 and SHP-2 combine with different sites
in the receptor complexes of IFN-gamma [28]. However,
SOCS3 and SHP-2 may have similar binding specificities.
Experiments have suggested that SOCS3 and SHP2 may
compete for same site (tyrosine Y759) in gp130 after IL-
6 stimulation [42,43]. In our model, SOCS1 and SHP-2
were capable of binding to the receptor complex of IFN-
gamma without mutual interference, whereas SOCS3
and SHP-2 could competitively bind to the receptor
complex. Distinct genes belonging to the SOCS family
are induced as immediate early genes (IEGs) down-
stream of different STATs and they can inhibit STAT ac-
tivation in a classical negative feedback loop [44]. It is
generally recognized that SOCS1 has an important role
in modulating IFN-gamma signalling [45], whereas
SOCS3 mainly affects IL-6 signalling [46]. It is also well
known that the STAT1 and STAT3 homodimers are dir-
ect transcription factors of the JAK/STAT pathway,
which play important roles in signal transduction during
IFN and gp130 receptor signalling [6]. However,
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induced after IFN-gamma stimulation in EC and that it
could inhibit signal transduction by IL-6 [18]. Qing et al.
observed that the STAT1 and STAT3 homodimers could
both be induced after IFN-gamma stimulation in MEFs,
which both bound to the same GAS element in the
SOCS3 promoter [19]. The sequence of this GAS elem-
ent is conserved in mice, rats and humans [47]. It was
shown that STAT3 activation was much stronger and
more prolonged in STAT1-null cells, and that SOCS3
was strongly induced in wild-type and STAT1-null cells,
while the levels of SOCS3 mRNA were greatly increased
in STAT3-null cells [19]. Thus, it is speculated that
STAT1 homodimers might also promote the transcrip-
tion of SOCS3 in the same way as STAT3 homodimers.
However, no experimental evidence indicates that
STAT3 homodimers can combine with the promoter re-
gion of SOCS1. Thus, our model does not regard STAT3
homodimers as an efficient transcription factor for
SOCS1. We added equation (N7) to our model to simu-
late the transcription of SOCS3 mRNA after its induc-
tion by STAT1 homodimers in the nucleus, which is
represented as (STAT1N*)2.
Thyrell et al. reported that IFN-alpha could affect the sig-
nal response of IL-6 in multiple myeloma, which resulted
in a decrease in STAT3 homodimer DNA-binding activity
and a shift from STAT3 homodimers to STAT1/3 heterodi-
mers [25]. Herrero et al. showed that pre-treatment with
IFN-gamma could affect the signal response of IL-10 in
macrophages, causing the IL-10-mediated activation pat-
tern to switch from STAT3 homodimers to STAT1/3 het-
erodimers [26]. These experimental results showed that
STAT1/3 heterodimers play important roles in the cross-
talk between different cytokines. The activation of STATs
after cytokine stimulation led to the formation of STAT
homo- and heterodimers [2,6].
Haan et al. reported that IL-6 stimulation of primary
human macrophages led to a different distribution of
STAT dimer species in the cytosol and nucleus. In particu-
lar, they showed that STAT1/3 heterodimers were present
in the cytosol and nucleus [48]. The size of STATs exceeds
90 kDa, which is far beyond the exclusion limit of the nu-
clear pores, so STATs need to be translocated actively into
the nucleus [2,6]. Tyrosine phosphorylation is not neces-
sarily required for STAT nuclear translocation [49]. Basic
residues (Lys410 and Arg413) are known to contribute to
the nuclear localization signals (NLSs) of dimeric STAT1
[50]. PP1 dephosphorylates STAT*s in the cytoplasm, while
PP2 dephosphorylates STAT*s in the nucleus, which leads
to STATs being returned to the cytosol [16,17,51]. It was
postulated that the nuclear export signals (NESs) in the
DNA-binding domain of STAT1 is comprised of the resi-
dues 399–410 [52]. The formation and dephosphorylation
of STAT1 and STAT3 homodimers in the cytosol andnucleus were modelled by Yamada et al. and Moya et al.,
respectively. Their models also described the translocation
of STAT1 and STAT3 homodimers from the cytosol to the
nucleus, and the export of dephosphorylated STAT mono-
mer from the nucleus to the cytoplasm [28,31]. In our
model, biochemical reactions (N8) - (N9) were added to
simulate the formation of STAT1/3 heterodimers in the
cytoplasm and nuclei. For simplicity, it was supposed that
only STAT1* and STAT3* could form STAT1/3 heterodi-
mers. Biochemical reaction (N10) was added to simulate
the STAT1/3 heterodimer translocation process from the
cytoplasm to the nucleus based on the translocation of
STAT homodimers. It was also assumed that STAT1/3 het-
erodimers could be dephosphorylated by PP1 and PP2,
which resulted in STAT export from the nucleus to the
cytoplasm. Biochemical reactions (N11)-(N16) were added
to simulate this process. The specific biological role of
STAT1/3 heterodimers remains obscure [6], so we did not
regard the STAT1/3 heterodimers as efficient transcription
factors in our model.
To construct the crosstalk model, we merged the com-
mon components from previous models, such as SHP-2,
PP1 and PP2. JAK1 and JAK2 are two species in the JAK
family, which play important roles in the signal responses
of IFN-gamma and IL-6 [40]. In previous studies, JAK1
and JAK2 were treated as JAK for simplicity [28,31]. JAK1
and JAK2 can combine with the receptors of IFN-gamma
and IL-6, but the signal transduction activities of IFN-
gamma and IL-6 may relate to specific types of JAKs. The
internal membrane proximal regions of JAK1 and JAK2,
which responds to the IFN-gamma signal, bind the IFN-
gamma receptor subunits IFNGR1 and IFNGR2 [53]. Dur-
ing IL-6 signalling, JAK1 and JAK2 are activated via the
conserved membrane proximal-binding domain of the
receptors, and JAK1 plays a major role in the signal re-
sponse to IL-6 [54]. Moreover, Guschin et al. suggested
that, although JAK2 was activated, it could not mediate
the efficient activation of STAT1 and STAT3 after IL-6
stimulation in the absence of JAK1 [55]. Thus, JAK2 may
share redundant functions with JAK1. In our model, we
used two different JAK species for IFN-gamma and IL-6
receptors, respectively.
Our model contains two main components: IL-6
signalling via the JAK/STAT3 pathway and IFN-gamma
signalling via the JAK/STAT1 pathway. There are multi-
level interactions between the two pathways. The model
contains 108 species, 192 kinetic parameters and 119
reactions, of which 103 reactions are based on previous
models whereas 16 reactions were new. To make the ex-
perimental results easier to compare, if not specified
otherwise, the concentrations of STAT1* and STAT3*
were the sum of the concentrations of all species con-
taining activated STAT1 and STAT3, respectively, in-
cluding their monomers and dimers.
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and IL-6 stimulation
First, we stimulated the model with IFN-gamma (0.1 nM)
for 12 h and found that STAT1* reached its maximum
concentration (350 nM) within about 1 h, before it
decreased rapidly due to the feedback inhibition of SOCS1
and SHP2. It finally reached a new steady state (60 nM)
after about 6 h. STAT3 was activated to reach its max-
imum concentration (60 nM) within about 1h and it
decreased rapidly to the control level after 2 h, whereas
the activation of STAT1 was much stronger than STAT3
after IFN-gamma stimulation (see Figure 1A). The signal
transduction profiles of these molecules were consistent
with previous experiment results, although there were
some differences in the signal strength and duration [18].Figure 1 Simulated time courses of species in the crosstalk model wi
(A) IFN-gamma stimulation induced much stronger activation of STAT1 tha
STAT3 than STAT1. (C) In a balanced competition model, IFN-gamma stimu
competition model, IL-6 stimulation induced similar activation of STAT1 an
stimulation induced more STAT1 and STAT3 homodimer formation than no
stimulation induced higher STAT1 and STAT3 homodimer formation than n
inactive SHP2, which did not combine with other molecules or complexes.Next, we stimulated the model with IL-6 (0.1 nM) for
12 h and found that STAT3* reached its maximum concen-
tration (350 nM) within about 0.5 h, before it decreased
rapidly due to feedback inhibition from SOCS3 and SHP2.
It reached a new steady state (40 nM) after about 6 h.
STAT1 was activated and reached its maximum concen-
tration (100 nM) within about 0.5 h, before it decreased
rapidly to the control level after 1.5 h, whereas the activa-
tion of STAT3 was much stronger than STAT1 after IL-6
stimulation (Figure 1B). The signal transduction profiles
of these molecules agreed with experiment results [20].
Next, same kinetic affinities were set for IFNR and gp130
in STAT1 and STAT3, respectively. As a result, IFN-
gamma and IL-6 stimulation caused similar strong activa-
tion of STAT1, STAT3, SOCS1 and SOCS3 (Figure 1C-D).th continuous exposure to IFN-gamma (0.1 nM) or IL-6 (0.1 nM).
n STAT3. (B) IL-6 simulation induced much stronger activation of
lation induced similar activation of STAT1 and STAT3. (D) In a balanced
d STAT3. (E) With no formation of STAT1/3 heterodimers, IFN-gamma
rmal conditions. (F) With no formation of STAT1/3 heterodimers, IL-6
ormal conditions. In the Figure, SHP2 represents the monomers of
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gamma and IL-6 stimulation did not agree with previous
experimental observations. These results demonstrated
the validity of our unbalanced competition model.
We also investigated the signal transduction profiles of
STAT homo- and heterodimers in the nucleus after IFN-
gamma and IL-6 stimulation, separately. After continuous
stimulation with IFN-gamma (0.1 nM) for 12 h, (STAT1N*)
2 reached its maximum concentration (65 nM) within
about 1 h and it maintained a new steady state (5nM) after
6 h, whereas (STAT3N*)2 only reached its maximal con-
centration (1 nM) after 1 h (Figure 1A). By contrast, IL-6
stimulation (0.1 nM) for 12 h made the (STAT3N*)2 level
reach its maximum concentration (90 nM) within about
0.5 h and it reached a new steady state (5 nM) after about
6 h, whereas (STAT1N*)2 only reached its maximal concen-
tration (1 nM) after 0.5 h (Figure 1B). Our results con-
firmed the experimental observations of Haan et al. who
showed that IL-6 stimulation led to STAT3 homodimers
predominating in the nucleus [48]. These results suggested
that IFN-gamma and IL-6 signalling preferentially activate
nuclear STAT homodimers. For the STAT1/3 heterodimers
(STAT1N*-STAT3N*) in the nucleus, however, both IFN-
gamma and IL-6 could induce a similar concentration/
strength, which reached its maximum concentration (50
nM) in about 0.5–1 h (Figure 2A–B). IFN-gamma and IL-6
could both activate STAT1 and STAT3, but fewer STAT1*
and STAT3* molecules were sequestered by STAT1/3 het-
erodimers, so its transcriptional activation function was
repressed. When the formation of STAT1/3 heterodimers
was blocked, the maximum concentrations of (STAT1N)*2
and (STAT3N)*2 both increased to about 15 nM after IFN-
gamma or IL-6 stimulation (Figure 1E-F). Thus, the forma-
tion of STAT1/3 heterodimers enhanced the preferential
signal transduction of IFN-gamma and IL-6.
SHP-2 knockout simulations were also performed to
characterize the effects of SHP-2. As shown in Figure 2A–B,
knocking out SHP-2 enhanced the signal responses of
IFN-gamma and IL-6, which agreed with previous experi-
mental observations. You et al. showed that IFN-gamma
could induce a higher signal response in SHP-2 null cells
[14]. Schapter et al. also reported that over-expression of
an inactive SHP-2 mutant in HepG2 cells enhanced STAT
activation after IL-6 stimulation [15]. After IFN-gamma or
IL-6 stimulation, however, the JAK/STAT pathway exhib-
ited different features to those when knocking out SHP-2.
Without SHP-2, IFN-gamma stimulation induced higher
levels of STAT1* and STAT3* (about 150%) than that in
normal conditions (Figure 2A). By contrast, IL-6 stimula-
tion induced rapid increases in STAT1* and STAT3*, the
maximum concentrations of which reached 900 nM and
500 nM, respectively, which was about three times higher
than that in normal conditions. After IL-6 stimulation, we
also observed that SOCS3 reached a peak value about 75nM at 2 h, which inhibited signal transduction by IL-6
and quickly caused the concentrations of STAT1* and
STAT3* to drop to normal levels after 3 h (Figure 2B).
Knockout simulations were also performed for SOCS1
and SOCS3. As shown in Figure 2C–D, knocking out
SOCS1 enhanced the activation of STAT1 after IFN-
gamma stimulation, while knocking out SOCS3 enhanced
the activation of STAT3 after IL-6 stimulation. Our simu-
lation results agreed with previous experimental observa-
tions. Brysha et al. demonstrated that in vitro and in vivo
hepatocytes lacking SOCS-1 exhibited prolonged activa-
tion of STAT1 after IFN-gamma stimulation, which corre-
lated with the dramatically increased sensitivity to the
toxic effects of IFN-gamma [13]. Niwa et al. reported that
inhibition of SOCS3 expression enhanced the activation of
STAT3 and cell growth [56]. After IFN-gamma or IL-6
stimulation, however, the JAK/STAT pathway exhibited
different features when knocking out SOCS1 or SOCS3.
Without SOCS1, IFN-gamma stimulation induced higher
levels of STAT1* and STAT3* (about 250%) compared
with those in normal conditions (Figure 2C). Without
SOCS3, however, IL-6 stimulation induced increases in
STAT1* and STAT3*, the maximum concentrations of
which reached 700 nM and 300 nM, respectively, which
were about double those in normal conditions. After IL-6
stimulation, we also observed that SHP-2 dropped to a
low level of about 80 nM at 1 h, which attenuated signal
transduction by IL-6 and caused the concentrations of
STAT1* and STAT3* to fall slowly after 3 h (Figure 2D).
Thus, SOCS1 and SOCS3 had different interaction pat-
terns with SHP-2. SOCS1 and SHP-2 synergistically regu-
lated signal transduction by IFN-gamma. Knocking out
SOCS1 or SHP-2 enhanced the integral activation of
STAT1 induced by IFN-gamma stimulation. By contrast,
SOCS3 and SHP-2 regulated signal transduction by IL-6
in a more complementary manner. Knocking out SHP-2
alone enhanced the rapid response of the IL-6 signal, due
to a compensatory increase in SOCS3. Knocking out
SOCS3 also led to lower levels of SHP-2, which caused a
slow decline in STAT1* and STAT3* 3 h after IL-6 stimu-
lation. Simulations of the combined knockout of SHP-2
and SOCS were performed to characterize their joint
effects on IFN-gamma and IL-6 stimulations. First, we sti-
mulated the SHP-2 and SOCS1 combined knockout
model with IFN-gamma (0.1 nM) for 12 h and found that
STAT1* reached its maximum concentration (960 nM)
within about 2 h while STAT3* reached its maximum con-
centration (900 nM) within about 3 h (Figure 2E). IFN-
gamma stimulation induced a similar strength of STAT1*
and STAT3* in SHP-2 and SOCS1 combined knockout
conditions. We then stimulated the SHP-2 and SOCS3
combined knockout model using IL-6 (0.1 nM) for 12 h
and found that STAT1* and STAT3* both quickly reached
their maximal concentration of 950 nM and 980 nM,
Figure 2 Simulated time courses of species in the crosstalk model with continuous exposure to IFN-gamma (0.1 nM) or IL-6 (0.1 nM)
after knocking out SHP2 and/or SOCSs. (A) Without SHP-2, IFN-gamma stimulation induced higher levels of STAT1* and STAT3* (about 150%)
than normal conditions. (B) Without SHP-2, IL-6 stimulation induced rapid increases in STAT1* and STAT3*. (C) Without SOCS1, IFN-gamma
stimulation induced higher levels of STAT1* and STAT3* (about 250%) than normal conditions. (D) Without SOCS3, IL-6 stimulation induced rapid
increases in STAT1* and STAT3*, the maximum concentrations of which reached 900 nM and 500 nM, respectively. (E) With SHP-2 and SOCS1
combined knockout, IFN-gamma stimulation produced a similar strength of STAT1* and STAT3*, which both rapidly reached their maximum
concentrations of 960 nM and 900 nM, respectively. (F) With SHP-2 and SOCS3 combined knockout, IL-6 produced similar strengths of STAT1*
and STAT3*, which both rapidly reached their maximum concentrations of 950 nM and 980 nM, respectively. (G) With SHP-2 and SOCS1
combined knockout, the level of (IFN-R-JAK)2* increased significantly after IFN-gamma stimulation. (H) With SHP-2 and SOCS3 combined
knockout, the level of (IL6-gp80-gp130-JAK)2* increased significantly after IL-6 stimulation.
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also induced similar strengths of STAT1* and STAT3* in
SHP-2 and SOCS3 combined knockout conditions. Thus,
the combined knockout of SHP-2 and SOCSs abolished
the preferential activation of IFN-gamma and IL-6. The
unbalance competition between STAT1 and STAT3 was
not related directly to SHP-2 and SOCSs, but SHP-2 and
SOCSs combined with the activated receptor complexes
and inhibited signal transduction via the JAK/STAT path-
way [2,6,12]. Therefore, we deduced that SHP-2 and
SOCSs could limit the concentration of active receptor
complexes, which indirectly affected the preferential acti-
vation of IFN-gamma and IL-6. Therefore, we investigated
the signal transduction profiles of the activated receptor
complexes in response to IFN-gamma and IL-6 with and
without knocking out SHP-2 and/or SOCSs. Without any
knockout, (IFN-R-JAK)2* reached its maximum concen-
tration (0.1 nM) in about 0.5 h after IFN-gamma, before
decreasing rapidly. After knocking out SHP-2, the level of
(IFN-R-JAK)2* increased by about 120% compared with
that in normal conditions. Without SOCS1, (IFN-R-JAK)
2* increased rapidly and reached a new steady state (0.35
nM) after 2 h, whereas the combined knockout of SHP-2
and SOCS1 caused the level of (IFN-R-JAK)2* to increase
significantly, reaching 4.5 nM in 12 h, which was about
forty time as high as that in normal conditions (Figure 2G).
Without any knockout and with IL-6, (IL6-gp80-gp130-
JAK)2* reached its maximum concentration (0.15 nM)
within about 0.25 h, before decreasing rapidly. After
knocking out SHP-2, (IL6-gp80-gp130-JAK)2* increased
rapidly and it reached its maximum concentration of 1.4
nM in 0.25 h, which was about nine times that in normal
conditions, although it quickly returned to a normal level
after 0.5 h. With SOCS3 knock out, the (IL6-gp80-gp130-
JAK)2* level increased and reached a new steady state (0.15
nM) after 1 h. With the combined knockout of SHP-2 and
SOCS3, the levels of (IL6-gp80-gp130-JAK)2* increased
significantly and reached a new steady state (5 nM) after
1 h, which was about 35 times that in normal conditions
(Figure 2H). The simulation results demonstrated that with
the SHP-2 and SOCSs combined knockout, the levels of
(IFN-R-JAK)2* and (IL6-gp80-gp130-JAK)2* increased sig-
nificantly after IFN-gamma and IL-6 stimulation. STAT1
and STAT3 competed for the same motifs in IFNR and
gp130, but there was sufficient (IFN-R-JAK)2* and (IL6-
gp80-gp130-JAK)2*, so the preferential activations of IFN-
gamma and IL-6 were abolished. These simulated observa-
tions still await further experimental verification.
Responses of the crosstalk model after disrupting STAT1
and STAT3
The effect of STAT3 on signal transduction via the JAK/
STAT pathway was analyzed by varying the initial concen-
tration of STAT3 in a range of 0–2000 nM. We found thatchanging the STAT3 level did not significantly affect the
state of STAT1* after IFN-gamma stimulation (Figure 3A),
which was consistent with previous experimental observa-
tions [22]. By contrast, the level of STAT1* was clearly
affected by the initial STAT3 concentration in response to
IL-6. In particular, when STAT3 was knocked out, STAT1
was more phosphorylated and for longer, so STAT1*
reached its maximum concentration (180 nM) in about
1 h, which was about double that in normal conditions. Fi-
nally, it reached a new steady state (50 nM) after about
7 h (Figure 3B). This was consistent with previous experi-
mental results, although there were some differences in
the signal strength and duration [20]. The different signal
responses to IFN-gamma and IL-6 during STAT3 disrup-
tion may explain why IL-6, but not IFN-gamma, could
trigger apoptosis and inhibit the in vivo growth of human
malignant T cells after knocking out STAT3 [22]. Next, we
analyzed the effect of STAT1 on signal transduction via
the JAK/STAT pathway by varying the initial concentra-
tion of STAT1 in a range of 0–2000nM. We found that
changing the initial concentration of STAT1 did not sig-
nificantly affect the level of STAT3* after IL-6 stimulation
(Figure 3C). By contrast, the level of STAT1 dramatically
affected the status of STAT3* after IFN-gamma stimula-
tion. When we knocked out STAT1 in our model, IFN-
gamma stimulation also led to much stronger activation
of STAT3, which caused a significant increase in the levels
of STAT3*. It finally reached a new steady state (220 nM)
after 1 h, which was about three times that in normal
conditions (Figure 3D). Our simulation results were con-
sistent with previous experimental observations [19].
Therefore, IFN-gamma and IL-6 signalling could mutually
switch in the conditions of STAT1 or STAT3 knockout,
which agreed very well with previous experimental obser-
vations [19,20].
After IFN-gamma and IL-6 stimulation, the recruit-
ment of STAT1 and STAT3 to the activated receptor
complexes directly affected their phosphorylation, which
has important roles in signal transduction by IFN-
gamma and IL-6 [34-36]. In our unbalanced competition
model, STAT1 and STAT3 had different affinities for
IFNR and gp130, so we deduced that disrupting STAT1
and STAT3 may have different effects on the recruit-
ment of STAT1 and STAT3. Next, we investigated the
effect of changing the initial concentration of STAT1
and STAT3 on the associations of STATs with activated
receptor complexes in response to IFN-gamma and IL-6.
Our simulation results demonstrated that changing the
concentration of STAT3 had little effect on the forma-
tion of (IFN-R-JAK)2*-STAT1 (Figure 3E), whereas alter-
ing the STAT1 level significantly affected the formation
of (IFN-R-JAK)2*-STAT3 (Figure 3F) after IFN-gamma
stimulation. Our simulations also showed that the for-
mation of (IL6-gp80-gp130-JAK)2*-STAT3 was almost
Figure 3 Dependency of JAK/STAT pathway activation on the initial concentrations of STATs. (A) The activation of STAT1 was mainly
independent of the concentration of STAT3 after IFN-gamma simulation. (B) The concentration of STAT3 significantly affected the activation of
STAT1 after IL-6 simulation. (C) The activation of STAT3 was mainly independent of the concentration of STAT1 after IL-6 simulation. (D) The
concentration of STAT1 significantly affected the activation of STAT3 after IFN-gamma simulation. (E) Recruitment from STAT1 to (IFN-R-JAK)2*
was mainly independent of the concentration of STAT3 after IFN-gamma simulation. (F) The concentration of STAT1 significantly affected
recruitment from STAT3 to (IFN-R-JAK)2*.
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although changing the STAT3 level significantly affected
the formation of (IL6-gp80-gp130-JAK)2*-STAT1(data
not shown). Therefore, the unbalanced competition be-
tween STAT1 and STAT3 for IFNR and gp130 was not
only the pivotal mechanism for the preferential activa-
tion of IFN-gamma and IL-6, but it also determined the
recruitment of STAT1 and STAT3 to the activated re-
ceptor complexes.
Responses of the crosstalk model to combined
stimulation with IFN-gamma and IL-6
We considered a combined stimulation protocol where
the model was stimulated with IFN-gamma (0.1 nM) and
IL-6 (0.1 nM) together for 12 h. Figure 4A shows thatcompared with the separate treatments, the combined
stimulation induced higher activation of the JAK/STAT
pathway. The dynamic responses of the JAK/STAT path-
way were consistent with previous results reported in the
literature [18]. In the previous section, we showed that
IFN-gamma and IL-6 could activate both STAT1 and
STAT3, which may explain the higher activation of STAT1
and STAT3 after combined stimulation. However, when
STAT1 could only be activated by IFN-gamma and STAT3
could only be activated by IL-6, combined stimulation still
caused greater activation of STAT1 and STAT3 than sep-
arate stimulation (Figure 4B). Thus, we inferred that other
mechanism may play important roles in this phenomenon.
PP1 and PP2 are two different types of phosphatases that
dephosphorylate STAT*s in the cytoplasm and nuclei,
Figure 4 Simulated time courses of species in the crosstalk model after combined stimulation with IFN-gamma and IL-6. (A) Combined
stimulation with IFN-gamma and IL-6 induced higher activation of STAT1 and STAT3 than separate treatments. (B) A setting where STAT1 could
only be activated by IFN-gamma and STAT3 could only be activated by IL-6 did not abolish the higher activation of STAT1 and STAT3 compared
with individual stimulation experiment. (C) Combined stimulation with IFN-gamma and IL-6 reduced the level of PP1 compared with individual
treatments. (D) Combined stimulation with IFN-gamma and IL-6 reduced the level of PP2 compared with the individual treatments. (E) Without
the formation of STAT1/3 heterodimers, combined stimulation with IFN-gamma and IL-6 did not induce higher levels of (STAT1N*)2 and
(STAT3N*) compared with normal conditions.
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both PP1 and PP2 were fixed and only the monomers
could combine and dephosphorylate the newly generated
STAT*s. We then investigated the signal transduction pro-
files of PP1 and PP2 in response to IFN-gamma and/or
IL-6 stimulation, and we found that combined stimulation
with IFN-gamma and IL-6 could activate STAT1 and
STAT3, which resulted in lower levels of PP1 and PP2
than the separate treatments (Figure 4C–D). After com-
bined stimulation, the activation of STAT1 prevented
STAT3 from being dephosphorylated and vice versa. This
mechanism contributed to the higher activation of STAT1
and STAT3 after combined stimulation with IFN-gamma
and IL-6.Signal transduction via the JAK/STAT pathway
depended on the formation of STAT homodimers [10],
which are regarded as the main transcription factors
during IFN-gamma and IL-6 signalling [2,8]. We further
investigated whether combined stimulation with IFN-
gamma and IL-6 could induce higher (STAT1N)*2 and
(STAT3N)*2 than separate treatments. Figure 4A shows
that 12 h after combined stimulation, the STAT homodi-
mers were not induced at a higher level than the separ-
ate treatments. However, STAT1N*-STAT3N* reached
their maximum concentration (200 nM) within about
1 h, which was about 3 time higher than the individual
treatment. The formation of STAT1N*-STAT3N* greatly
restricted the formation of STATs homodimers. After we
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maximum concentrations of (STAT3N)*2 and (STAT1N)*2
increased to about 100 nM with combined stimu-
lation (Figure 4E). Combined stimulation with IFN-
gamma and IL-6 led to greater activation of both STAT1
and STAT3, but the formation of STAT1/3 heterodimers
played an important role in preventing mutual strengths
between IFN-gamma and IL-6 signalling.
Responses of the crosstalk model to successive IFN-
gamma and IL-6 stimulation
We analyzed previous studies that focused on the inter-
actions between IFN-gamma and IL-6 signalling and
found that their interactions were asymmetric. Bluyssen
et al. reported that pre-treatment of EC with IFN-
gamma significantly decreased STAT3* induction by IL-
6 without affecting the total amount of STAT3 [18]. By
contrast, Kaur et al. reported that STAT1 activation
induced by IFN-gamma was mainly unchanged after
pre-treatment IL-6 or other gp130-related cytokines in
SH-SY5Y human neuroblastoma cells [24]. We tried to
provide a reasonable explanation for the asymmetric
interactions between IFN-gamma and IL-6 using simula-
tion experiments with our model.
First, we stimulated the model with IFN-gamma (0.1
nM) for 12 h, which we started 2 h prior to IL-6 (0.1 nM)
stimulation. IL-6 slightly increases the level of STAT3*, but
pre-treatment with IFN-gamma significantly decreased
STAT3* induction by IL-6 (Figure 5A). This was consistent
with the results reported by Bluyssen et al. [18]. SOCS3 is
a negative regulator of IL-6 signalling and it can be induced
by IFN-gamma stimulation, so we deduced that SOCS3
may have an important role during inhibition. When we
knocked out SOCS3, the inhibitory effect of IFN-gamma
on STAT3* induction by IL-6 was eliminated completely
(Figure 5B). These results showed that SOCS3 was an es-
sential component in the inhibition of IFN-gamma to IL-6
signalling. We also found that the expression of SOCS3
had a time delayed feedback, which significantly increased
1 h after IFN-gamma stimulation. Therefore, we deduced
that temporal pre-treatment with IFN-gamma may not
have induced sufficient SOCS3 to inhibit IL-6 signalling.
Figure 5C shows that temporal pre-treatment with IFN-
gamma partly inhibited IL-6 signalling and that the dur-
ation of pre-treatment with IFN-gamma needed to be
longer than 1 h to achieve this inhibition. We then investi-
gated how pre-treatment with IL-6 affected the IFN-
gamma signal response. Our simulation results showed
that pre-treatment with IL-6 for 2 h only slightly reduced
the amount of STAT1* and did not inhibit the signal re-
sponse of IFN-gamma (Figure 5D), while changing the dur-
ation of the pre-treatment with IL-6 still had no obvious
effect on the signal response of IFN-gamma. Moreover,
pre-treatment for less than 1 h had almost no effect on thestate of STAT1* (Figure 5E). These simulation results were
consistent with the results reported by Kaur et al. [24]. We
inferred that the asymmetric interactions between IFN-
gamma and IL-6 signalling were related mainly to the dif-
ferent inhibition efficiencies of SOCS1 and SOCS3. SOCS1
could be induced by (STAT1N)*2 after IL-6 stimulation,
but SOCS1 induction by IL-6 is not sufficient to inhibit
IFN-gamma signalling. After IFN-gamma stimulation,
however, SOCS3 could be induced by (STAT1N)*2 and
(STAT3N)*2, which achieved the inhibition from IFN-
gamma to IL-6.
The formation of STAT1/3 heterodimers also contribu-
ted to the asymmetric interactions between IFN-gamma
and IL-6 signalling. As previously described, the formation
of STAT1/3 heterodimers enhanced the preferential signal
transduction of IFN-gamma and IL-6 by sequestering a
fraction of STAT1* and STAT3*. After we abolished the
formation of STAT1/3 heterodimers, the maximum con-
centration of SOCS1 induced by IL-6 increased to 4.2 nM
within about 1.5 h, and IL-6 exhibited a greater capacity
for inhibiting IFN-gamma signalling (Figure 5F). Abolish-
ing the formation of STAT1/3 heterodimers also enhanced
the inhibition from IFN-gamma to IL-6 (Figure 5G). In
addition, the mechanism of (STAT1N*)2 inducing SOCS3
also played an important role in the asymmetric interac-
tions. The concentration of (STAT3N*)2 induced by IFN-
gamma stimulation was very low due to the sequestering
effect of STAT1/3 heterodimers. Therefore, we deduced
that SOCS3 induction by (STAT3N*)2 was not sufficient
to achieve the inhibition from IFN-gamma to IL-6. In-
deed, when we abolished the (STAT1N)*2 induction of
SOCS3, the inhibition from IFN-gamma to IL-6 was
clearly mitigated (Figure 5H). IFN-gamma only slightly
reduced the activation of STAT3 induction by IL-6, which
did not agree with previous experimental observations
[18]. Therefore, (STAT1N*)2 induction of SOCS3 was es-
sential for the inhibition from IFN-gamma to IL-6 during
signal transduction.
Argument for the non-competitive model
Ho et al. reported that STAT3 did not affect the activation of
STAT1 during type I interferon responses [23]. They argued
that STAT3 did not suppress STAT1 activation via tyrosine
phosporylation and they excluded inhibitory mechanisms
such as the competition for docking sites and the inhibition
of signalling events upstream of STAT1 tyrosine phosphoryl-
ation. Based on their argument, we proposed an alternative
hypothesis for the combined pattern between STATs and the
receptors for IFN-gamma and IL-6 in addition to our previ-
ous competition model, which we refer to as the non-
competitive model. In the non-competitive model, STAT1
and STAT3 do not compete for the same docking sites of
IFNR and gp130, so we considered that STAT1 and STAT3
could bind different phosphorylated docking sites in IFNR
Figure 5 Simulated time course of species in the crosstalk model of IL-6 after pre-treatment with IFN-gamma or IFN-gamma after pre-
treatment with IL-6. (A) Pre-treatment with IFN-gamma significantly decreased the activation of STAT3 induced by IL-6. (B) Without SOCS3, the
inhibitory effect of IFN-gamma on STAT3* induction by IL-6 was completely eliminated. (C) Temporal pre-treatment with IFN-gamma partly
inhibited IL-6 signalling. (D) Pre-treatment with IL-6 reduced the amount of STAT1* only slightly and did not inhibit the response of IFN-gamma.
(E) Changing the length of pre-treatment with IL-6 did not affect the signal response of IFN-gamma. (F) Without the formation of STAT1/3
heterodimers, IL-6 had a higher capacity to inhibit IFN-gamma signal transduction. (G) Without the formation of STAT1/3 heterodimers, IFN-
gamma had a higher capacity to inhibit IL-6 signal transduction. (H) Abolishing (STAT1N)*2 induction of SOCS3 inhibited the IFN-gamma effects
on IL-6.
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erations, we added the new biochemical reactions (N17) -
(N20) (see “non-competitive model” in Additional file 1) to
simulate the mutually independent combination of STAT1
and STAT3 with the receptor complexes. STAT3 did not
suppress the activation of STAT1 via tyrosine phosphoryl-
ation, so we considered that the combination of STAT3
with receptor complexes did not suppress the phosphoryl-
ation processes of STAT1 and vice versa. Based on these
considerations, we added the new biochemical reactions
(N21) - (N24) to simulate the mutually independent phos-
phorylation of STAT1 and STAT3 within receptor com-
plexes. In addition, we estimated the parameters for
reactions (N17)-(N24) and re-estimated the parameters for
reactions (N1)-(N6) to fit the non-competitive model
(Additional file 1: Table S5). Detailed descriptions of the
non-competitive model written in COPSI (using the file-
name extension “.cps”) are available in Additional file 2.
First, we conducted simulation experiments using IFN-
gamma and IL-6 stimulation separately, as in the previous
study, and we aimed to estimate and optimize the parameters
of the new non-competitive model. As shown in Figure 6A-B,
our computational simulation indicated that the activation of
STAT1 was much greater than STAT3 after IFN-gamma
stimulation, whereas the activation of STAT3 was much
greater than STAT1 after IL-6 stimulation, which agreed with
previous experiment results despite some deviations in the sig-
nal strength and durations [19,21]. Next, the same kinetic af-
finities were used for IFNR and gp130 with STAT1 and
STAT3, respectively. IFN-gamma and IL-6 stimulation caused
similar strong activation of STAT1, STAT3, SOCS1 and
SOCS3 (Figure 6C-D), which did not agree with previous ex-
perimental observations. These results demonstrated that the
non-competitive model using our estimated parameter set
could satisfy the basic simulation requirements and that it
simulated the preferential activation of IFN-gamma and IL-6.
Next, we executed the same series simulation experi-
ments described in the previous sections using the non-
competitive model. We found that the non-competitive
model approximately simulated the crosstalk between IFN-
gamma and IL-6 signalling in all conditions (data not
shown), with the exception of the disrupted STAT1 and
STAT3 conditions. Figure 6E shows that when we fixed the
concentration of STAT1 at 1000 nM and changed the con-
centration of STAT3 from 0, 500, 1000, to 2000 nM, the
states of STAT1* were obviously dependent on the level of
STAT3 after IFN-gamma stimulation. In particular, STAT1
was more strongly phosphorylated, and for longer, with
higher levels of STAT3, which were completely different
from the experimental observations reported by Regis et al.
[22]. Similarly, when we fixed the concentration of STAT3
at 1000 nM and changed the concentration of STAT1 from
0, 500, 1000, to 2000 nM, the states of STAT3* were also
obviously dependent on the level of STAT1 after IL-6stimulation (Figure 6F). Moreover, STAT3 was also more
strongly phosphorylated and for longer with higher levels
of STAT1, which did not agree with the experimental
observations of Dimberg et al. [57]. Indeed, the activation
of STATs was determined by the swing between phosphor-
ylation and dephosphorylation processes [6]. In the non-
competitive model, STAT1 and STAT3 did not suppress
the phosphorylation of each other, although they share the
phosphatases PP1 and PP2, so the activation of STAT1 pre-
vented STAT3 from being dephosphorylated and vice
versa. The disruption of the dynamic balance between the
phosphorylation and dephosphorylation of STAT1 and
STAT3 meant the responses of the non-competitive model
were hypersensitive to the initial concentrations of STAT1
and STAT3. Therefore, the non-competitive model may
not reflect the crosstalk mechanisms between IFN-gamma
and IL-6 signalling in a physiological environment. Thus,
alternative hypotheses should be proposed based on new
experimental observations. Here, we provide an integrated
platform that facilitates the verification of possible hypoth-
eses related to the crosstalk between IFN-gamma and IL-6
signalling in future work.
Sensitivity analysis of the competition model
In this study, we used computational simulation to demon-
strate the effectiveness of the competition model. Next, we
determined the dynamic characteristics of our model by
sensitivity analysis. The calculations used in the sensitivity
analysis are shown in the “Methods” section. The upstream
key regulatory molecules of (STAT1N*)2 and (STAT3N*)2
comprise cytokines, receptors, JAK, STAT1C, STAT3C,
PP1, PP2, and SHP2, and their initial concentrations were
considered in the sensitivity analysis. First, we applied a
sensitivity analysis to determine the relative sensitivity of
these components using IFN-gamma stimulation as the
input.
The results indicated that IFN-gamma, the receptor, JAK,
STAT1C, and PP2 were relatively important components of
the IFN-gamma-induced JAK/STAT signalling pathway
(Figure 7A). It was also noted that some of the initial con-
centrations, such as those of PP1 and STAT3C, had little
impact on the time course of (STAT1N*)2. In a previous
simulation, we found that the decline in the concentration
of PP2 was more obvious than that of PP1 during IFN-
gamma and IL-6 signal transduction (Figure 4C–D). We
deduced that the basic level of PP1 exceeded the demand of
IFN-gamma transduction, which agreed with the conclu-
sions of the previous study. The concentration of STAT3
did not affect the activation of STAT1, as described in the
previous section. Moreover, we found that the parameters
related to the key signalling components identified had rela-
tively significant effects on the time course of (STAT1N*)2,
as shown in Figure 7B. The reactions with the most sensitive
kinetic parameters were STAT1C phosphorylation by the
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tion. The SOCS1 synthesis, degradation, and negative regu-
lation processes were also very sensitive, which confirmed
the important role of the negative feedback factor SOCS1
during IFN-gamma signal transduction.Figure 6 Simulated time courses of species in the non-competitive m
(A) IFNγ stimulation induced much stronger activation of STAT1 than STAT
STAT1. (C) With balanced kinetic affinities, IFNγ stimulation induced similar
stimulation induced similar activation of STAT1 and STAT3. (E) STAT1 was p
STAT3 after IFNγ simulation. (F) STAT3 was phosphorylated more strongly aNext, we performed a sensitivity analysis using IL-6
stimulation as the input. The sensitivities of the initial con-
centrations and the critical kinetic parameters are shown
in Figure 7C and Figure 7D. The results indicated that the
reactions with PP2 negative regulation and JAKodel with continuous exposure to IFNγ (0.1 nM) or IL-6 (0.1 nM).
3. (B) IL-6 simulation induced much stronger activation of STAT3 than
activation of STAT1 and STAT3. (D) With balanced kinetic affinities, IL-6
hosphorylated more strongly and for longer with a higher level of
nd for longer with a higher level of STAT1 after IL-6 simulation.
Figure 7 Sensitivity analysis of the competition model. (A, B) indicate the sensitivities of the initial molecule concentrations and the reaction
rate constants after IFN-gamma stimulation. (C, D) indicate the sensitivities of the initial molecule concentrations and the reaction rate constants
after IL-6 simulation. The definition of the parameter sensitivity can refer to the “Methods” section. The positive (or negative) sensitivity values
indicate consistent (or opposite) percentage changes in output to the perturbation in the parameter compared to the nominal solution. The red
and blue bars represent positive and negative sensitivity values, respectively. For brevity, we only show the top 20 parameters with high
sensitivity values.
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described in previous sections, the concentration of STAT1
did not significantly affect the activation of STAT3 after
IL-6 stimulation, which was also confirmed by the sensitiv-
ity analysis. Similarly, we found that the SOCS3 synthesis,
degradation, and negative regulation processes were highly
sensitive to IL-6 stimulation, which confirmed the import-
ant role of the negative feedback factor SOCS3 during IL-
6signal transduction. In particular, we found that the phos-
phorylation of STAT3 in STAT1/3 heterdimers in the nu-
cleus also had a high impact on the state of (STAT3N*)2.
Overall, the sensitivity analysis determined the sensitive
components and parameters during JAK/STAT signal
transduction. These results provide valuable information
that may inform further investigations of regulation and
drug target identification in aberrant pathways. The
detailed results of the sensitivity analysis of the competition
model are shown in Additional file 1: Tables S6–S7.Sensitivity analysis of the non-competitive model
We also investigated the dynamic characteristic of the
non-competitive model by sensitivity analysis. First, we
applied sensitivity analysis to determine the critical com-
ponents with dominant effects where IFN-gamma stimu-
lation was used as the input. Figure 8A shows the
sensitivities to the initial concentrations, while the sensi-
tivities of the critical kinetic parameters are shown in
Figure 8B. There were some deviations in magnitude butthe non-competitive model yielded similar sensitivity results
to the competition model after IFN-gamma stimulation, ex-
cept the concentration of STAT3C had a higher sensitivity
to (STAT1N*)2 in the non-competitive model. This con-
firmed our previous conclusion that the responses of IFN-
gamma in the non-competitive model were hypersensitive
to the initial concentrations of STAT3. Next, we performed
a sensitivity analysis using IL-6 stimulation as the input.
Figure 8C shows the sensitivities to the initial concentra-
tions, while the sensitivities to the critical kinetic parameters
are shown in Figure 8D. We also found that the concentra-
tion of STAT1C was highly sensitive to (STAT3N*)2 in the
non-competitive model. In the previous section, simulation
results demonstrated the non-competitive model could not
accurately reflect the signal transduction of IL-6 and IFN-
gamma under the condition of disrupting of STATs. Here,
the sensitivity analysis confirmed the high sensitivity of
STATs in the non-competitive model. The detailed results
of the sensitivity analysis of the non-competitive model are
shown in Additional file 1: Tables S8–S9.Discussion
The results were affected by the limitations of our model. It
is important to consider these limitations because they form
the basis for future improvements. First, we only considered
three possible levels of crosstalk between IFNγ and IL-6 sys-
tems. Haan et al. showed that, after IL-6 stimulation, STAT1
phosphorylation was entirely dependent on JAK1 kinase
Figure 8 Sensitivity analysis of the non-competitive model. (A, B) indicate the sensitivities of the initial molecule concentrations and the
reaction rate constants after IFN-gamma stimulation. (C, D) indicate the sensitivities of the initial molecule concentrations and the reaction rate
constants after IL-6 simulation, respectively. The definition of the parameter sensitivity can refer to the “Methods” section. The positive (or
negative) sensitivity values indicate consistent (or opposite) percentage changes in output to the perturbation in the parameter compared to the
nominal solution. The red and blue bars represent positive and negative sensitivity values, respectively. For brevity, we only show the top 20
parameters with high sensitivity values.
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showed that, in response to IFN-gamma, SCR-family kinases
had to activate STAT3 (but not STAT1) via tyrosine phos-
phorylation [19]. Some mechanisms that contribute to the
specific signal responses of IFN-gamma and IL-6 were not
considered in this study. Second, our computational model
was a simplification of a biological process and it might not
reflect the true regulatory mechanism for the signal interac-
tions. Third, the simulation results in this study were affected
by assumptions made based on our experience, e.g., the
STAT1/3 heterodimers could be dephosphorylated by PP1
and PP2 in the cytoplasm and nucleus, respectively. Fourth,
our model had very rich dynamics parameters that were not
fully explored in this study. For simplicity, protein turnover,
receptor recycling, de novo synthesis and the degradation of
transcription factors were not included in the current model.
The ultimate aim of our research is to construct a universal
model that accurately reflects the crosstalk between IFN-
gamma and IL-6 signals. However, the signal responses to
cytokines may be cell type-dependent. Caldenhoven et al.
reported that the activation of STAT3 induced by IFN-
gamma was lineage-specific in human neutrophils [58].
Zhang et al. showed that IL-6 stimulation could induce
STAT1 phosphorylation in a dose- and time-dependent
manner in M1, R2 and U937 cells, although it had little effect
on STAT1 phosphorylation in 7TD1 and TF1 cells [21].
Bluyssen et al. argued that IL-6 did not activate STAT1 in
EC [18]. Furthermore, the concentrations of moleculeswithin the JAK/STAT pathway, such as STATs, are cell type-
dependent [6]. The experimental data are limited and not
systematic, so we had to create our model based on experi-
mental observations of many different cell types, while we
neglected certain contradictory experimental observations.
Therefore, it is not possible to expect that the dynamics pre-
dicted by our model will apply universally to all types of cells.
Thus, structure and parameters of the model may need some
adjustment to reflect signal transduction by IFN-gamma and
IL-6 in certain cell types. Finally, our crosstalk model was
based on experimentally established interactions, but further
experimental verification and improvements are required.
Our simulation results showed that STAT1/3 heterodi-
mers have three important functions during signal trans-
ductions from IFN-gamma to IL-6. First, the formation
of STAT1/3 heterodimers enhances the preferential sig-
nal transduction by IFN-gamma and IL-6 because it
sequesters a fraction of STAT1* and STAT3*. Second, the
formation of STAT1/3 heterodimers prevents mutual
reinforcement between IFN-gamma and IL-6 signalling.
Finally, the formation of STAT1/3 heterodimers limits the
reciprocal inhibition of IFN-gamma and IL-6 signalling. In
our simulations, therefore, the formation of STAT1/3 het-
erodimers dramatically affected the interaction between
the IFN-gamma and IL-6 systems, which suggests that
STAT1/3 heterodimers may be a potential target for recti-
fying abnormal signal transduction by IFN-gamma and
IL-6. The functional interference of STAT3 homodimers
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structure-activity relationship (SAR) studies could suc-
cessfully inhibit the growth of tumour cells [59,60]. How-
ever, the therapeutic potential of altering the formation of
STAT1/3 heterodimers has not been fully investigated.
Thus, further research is still required.
This is the first effort to construct a mathematical
model of the crosstalk between IFN and IL-6 signal-
ling. Moreover, our simulation results and theoretical
findings provide new insights into the dynamical
integration of IFN and IL-6 signals. The lack of ex-
perimental data and our current superficial under-
standing of signal transduction mean there are still
many defects in our crosstalk model. We will follow
current studies related to this issue and improve the
quality and veracity of model in our future research.
Conclusions
Based on previous models and new experimental obser-
vations, we developed the first crosstalk model of IFN-
gamma and IL-6 signalling. This theoretical study suc-
cessfully reproduced key experimental findings and
reached some definitive conclusions. First, the unba-
lanced competition between STAT1 and STAT3 for
IFNR and gp130 led to preferential activation of IFN-
gamma and IL-6. At the same time, the formation of
STAT1/3 heterodimers enhanced preferential signal
transduction by sequestering a fraction of STAT1* and
STAT3*. Moreover, SOCSs with SHP-2 limited the con-
centration of the activated receptor complexes of IFN-
gamma and IL-6, which also contributed to the preferen-
tial activation of IFN-gamma and IL-6. Second, the
unbalanced competition between STAT3 and STAT1
was the pivotal mechanism during the mutual switch be-
tween IFN-gamma and IL-6 signals after knocking out
STAT1 or STAT3. Finally, the formation of STAT1/3
heterodimers prevented the mutual reinforcement of
IFN-gamma and IL-6 signalling, and also limited the re-
ciprocal inhibition between IFN-gamma and IL-6 signal-
ling. Moreover, the process of STAT1 homodimer
induction of SOCS3 also contributed to asymmetric
interactions between IFN-gamma and IL-6 signalling.Methods
Three classes of kinetics were involved in our crosstalk
model. The mass-action equation for the molecular





where Kf and Kr are the rates of the forward and reverse
reactions. The Michaelis-Menten function (actually besplit into two Mass-Action reactions) for the enzymatic





K3 E þ P
where E is the enzyme; S is the substrate; ES is the
enzyme-substrate complex; P is the product; and K1, K2
and K3 are the rates of the reactions. The equation for




where AC represents a molecule in the cytoplasm; AN is
AC translocated from the cytoplasm to nuclei; B is the
catalyst; and Kf is the rate of the reaction.
Based on Yamada et al. [28] and Moya et al. [31], we
established the components of the IFN-gamma and IL-6
pathways, respectively, where the model parameters of
the two components were left unchanged. The equations
of these reactions are shown in Additional file 1 and the
kinetic parameters of these reactions are provided in
Additional file 1: Table S2-S3. Based on the possible
physiological mechanisms of IFN-gamma and IL-6
cross-regulation, we also added 16 new reactions (N1)-
(N16) in our crosstalk model. The equations of these
reactions are listed below (New biochemical reactions
added to the crosstalk model) while a graphic descrip-
tion of these reaction is shown in Figure 9. The kine-
tic parameters of these new reactions are provided in
Additional file 1: Table S1.
New biochemical reactions added to the crosstalk model
STAT3C binding: this positive reaction describes
STAT3C binding with the receptor complex of IFN-
gamma while the reverse reaction describes the dissoci-
ation of STAT3C.




IFN  R JAKð Þ2
 STAT3C
ðN1Þ
STAT3C activation: this reaction describes the activa-
tion of STAT3C by the receptor complex of IFN-gamma.
IFN  R JAKð Þ2
  STAT3C→nk2 IFN  R JAKð Þ2
 þ STAT3C 
ðN2Þ
STAT3C* binding: this positive reaction describes
STAT3C* binding with the receptor complex of IFN-
Figure 9 Schematic description of the newly added
biochemical reactions in the crosstalk model. In the diagram: R
represents a receptor; C represents a species in the cytoplasm; N
represents a species in the nucleus; 2 represents dimers; and *
represents the activation state. mRNA-SOCS3N represents the SOCS3
mRNA in the nucleus. Arrows indicate the reaction direction.
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ation of STAT3C*.




IFN  R JAKð Þ2  STAT3C ðN3Þ
STAT1C binding: this positive reaction describes
STAT1C binding with the receptor complex of IL-6
while the reverse reaction describes the dissociation of
STAT1C.




IL6 gp80 gp130 JAKð Þ2
 STAT1C
ðN4Þ
STAT1C activation: this reaction describes the activa-
tion of STAT3C by the receptor complex of IL-6.
IL6 gp80 gp130 JAKð Þ2
 STAT1C→nk5 IL6 gp80 gp130 JAKð Þ2
 þSTAT1C
ðN5Þ
STAT1C* binding: this positive reaction describes
STAT3C* binding with the receptor complex of IL-6while the reverse reaction describes the dissociation of
STAT1C*.




IL6 gp80 gp130 JAKð Þ2
 STAT1C ðN6Þ
mRNA-SOCS3 transcript: this reaction describes
SOCS3 mRNA transcription after its induction by
STAT1 homodimers in the nucleus.
d mRNA  SOCS3N½ =dt
¼ V max STAT1Nð Þ2= STAT1Nð Þ2þ Km½ 
ðN7Þ
STAT1/3 heterodimer formation: this positive reaction
describes the formation of STAT1/3 heterodimers in the
cytoplasm while the reverse reaction describes their dis-
sociation.





STAT1/3 heterodimer formation: this positive reaction
describes the formation of STAT1/3 heterodimers in the
nucleus while the reverse reaction describes their dis-
sociation.





STAT1/3 heterodimer translocation: this reaction describes
the nuclear importation of STAT1/3 heterodimers.
STAT1C  STAT3C  →nk10 STAT1N
 STAT3N ðN10Þ
PP1 binding: this positive reaction describes PP1 bind-
ing with STAT1/3 heterodimers in the cytoplasm while
the reverse reaction describes their dissociation.






PP2 binding: this positive reaction describes PP2 bind-
ing with STAT1/3 heterodimers in the nucleus while the
reverse reaction describes their dissociation.
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activation of STAT1 in STAT1/3 heterodimers by PP1 in
the cytoplasm.
PP1 STAT1C  STAT3C  →nk13PP1
þ STAT1C þ STAT3C ðN13Þ
STAT3C inactivation: this reaction describes the inactivation
of STAT3 in STAT1/3 heterodimers by PP1 in the cytoplasm.
PP1 STAT1C  STAT3C  →nk14PP1
þ STAT1C  þSTAT3C ðN14Þ
STAT1N inactivation: this reaction describes the in-
activation of STAT1 in STAT1/3 heterodimers by PP2 in
the nucleus.
PP2 STAT1N  STAT3N  →nk15PP2
þ STAT1N þ STAT3N ðN15Þ
STAT3N inactivation: this reaction describes the inactivation
of STAT3 in STAT1/3 heterodimers by PP2 in the nucleus.
PP2 STAT1N  STAT3N  →nk16PP2
þ STAT1N  þSTAT3N ðN16Þ
where R represents the receptor; C represents a species within
the cytoplasm; N represents a species within nuclei; 2 repre-
sents dimers; and * represents the activation state. mRNA-
SOCS3N represents the SOCS3 mRNA in the nucleus;
(STAT1N*)2 represents phosphorylated STAT1 homodimers
in the nucleus; Vmax represents the maximum reaction
velocity of the SOCS3-mRNA transcription; Km represents
half of the substrate concentration when the enzymatic reac-
tion reaches its maximum reaction velocity.
Using this reaction scenario, we established systematic
models that were described using ordinary differential
equations (ODEs). COPASI (http://www.copasi.org/) and
CellDesigner (http://www.celldesigner.org/) were used to
calculate the model states and solve the ODE models
[61,62]. Detailed descriptions of the model written in
COPSI (using the filename extension “.cps”) are available
in Additional file 2.
Sensitivity analysis
The sensitivity analysis determined the change in the
output after a tiny perturbation in the initial state or the
reaction parameters. Thus, a perturbation Δx in the par-
ameter set induced an overall state change Δy and the
sensitivity was defined as Δy/Δx, which was normalized
with respect to the actual values of the phenomenon
investigated and the parameter x/y. Experimental studies
have shown that phosphorylated STAT dimers in the
nucleus are critical transcription factors for target gene
activation in the JAK/STAT pathway. Therefore, oursensitivity analysis considered (STAT1N*)2 and
(STAT3N*)2 as the outputs of IFN-gamma and IL-6 sig-
nalling, respectively. In this study, Δy was defined as the
change in the concentration of (STAT1N*)2 or
(STAT3N*)2 after 1.5 h, which adequately represented the
signal transduction strength of IFN-gamma or IL-6. The
perturbation ranges of each parameter were set as 30% of
the actual absolute value to avoid errors in the sensitivity
estimates. COPASI and CellDesigner were used to calcu-
late the sensitivity.
Additional files
Additional file 1: This file contains one figure, nine tables, and
description of the biochemical reactions in the crosstalk model and
the non-competitive model. Figure S1 shows the overall structure of
the crosstalk model. Table S1 lists the parameters and values of the
newly added reactions in the crosstalk model. Table S2 lists the
parameters and values of the IFN-gamma part of the crosstalk model.
Table S3 lists the parameters and values of the IL-6 part of the crosstalk
model. Table S4 lists the state variables of the model and their initial
values. Table S5 lists the re-estimated parameters and their values in the
non-competitive model. Table S6 lists the results of the sensitivity
analysis for variations in the concentrations of the pathway components
in the competition model. Table S7 lists the results of the sensitivity
analysis for variations in the kinetic parameters in the competition model.
Table S8 lists the results of the sensitivity analysis for variations in the
concentrations of pathway components in the non-competitive model.
Table S9 lists the results of the sensitivity analysis for variations in the
kinetic parameters in the non-competitive model. All of the biochemical
reactions investigated in this study are described in this file, which
contains the newly added biochemical reactions, the IFN-gamma and IL-
6 parts of the crosstalk model, and the newly added reactions in the
non-competitive model.
Additional file 2: This file contains the crosstalk model and the
non-competitive model written in COPASI, which can be executed
using COPASI version 4.7.
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